title: Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins.
abstract: Purified proteins such as antibodies are widely used as therapeutic agents in clinical medicine. However, clinical-grade proteins for therapeutic use require sophisticated technologies and are extremely expensive to produce. In vivo secretion of therapeutic proteins by genetically engineered human cells may advantageously replace injection of highly purified proteins. The use of gene transfer methods circumvents problems related to large-scale production and purification and offers additional benefits by achieving sustained concentrations of therapeutic protein with a syngenic glycosylation pattern that make the protein potentially less immunogenic. The feasibility of the in vivo production of therapeutic proteins by diverse cells/tissues has now been demonstrated using different techniques, such as ex vivo genetically modified cells and in vivo gene transfer mediated by viral vectors.
authors: Molecular Immunology Unit, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain.
authors: David
authors: D
authors: Sánchez-Martín
authors: Laura
authors: L
authors: Sanz
authors: Luis
authors: L
authors: Álvarez-Vallina
mesh_terms: D000906:Antibodies / Q000378:metabolism*; D000917:Antibody Formation; D005818:Genetic Engineering / Q000191:economics; D015316:Genetic Therapy / Q000191:economics / Q000639:trends; D006801:Humans; D011506:Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D000906:Antibodies; D011506:Proteins